CWP
BMRN icon

CFM Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

CFM Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,600
Closed -$814K – 194
2020
Q2 		$814K Hold
6,600
– – 0.31% 65
2020
Q1 		$558K Hold
6,600
– – 0.26% 73
2019
Q4 		$588K Buy
+6,600
New +$499K 0.22% 79

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CFM Wealth Partners's BMRN Position: Q3 2020 in Review

CFM Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 6,600 shares — an estimated $814K sold.

CFM Wealth Partners first reported a position in BMRN in Q4 2019 and held it in 3 quarters. The position peaked at $814K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • CFM Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • CFM Wealth Partners sold 6,600 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $814K.
  • CFM Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • CFM Wealth Partners's BioMarin Pharmaceuticals position peaked at $814K in Q2 2020.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on CFM Wealth Partners's 13F filing for Q3 2020, filed 10 Nov 2020.